OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer
Patrícia M. R. Pereira, Komal Mandleywala, Sébastien Monette, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 29
Patrícia M. R. Pereira, Komal Mandleywala, Sébastien Monette, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 29
Showing 1-25 of 29 citing articles:
Endocytosis in cancer and cancer therapy
Blerida Banushi, Shannon R. Joseph, Benedict Lum, et al.
Nature reviews. Cancer (2023) Vol. 23, Iss. 7, pp. 450-473
Closed Access | Times Cited: 101
Blerida Banushi, Shannon R. Joseph, Benedict Lum, et al.
Nature reviews. Cancer (2023) Vol. 23, Iss. 7, pp. 450-473
Closed Access | Times Cited: 101
Mechanisms of Resistance to Antibody–Drug Conjugates
Rachel O. Abelman, Bogang Wu, Laura M. Spring, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1278-1278
Open Access | Times Cited: 58
Rachel O. Abelman, Bogang Wu, Laura M. Spring, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1278-1278
Open Access | Times Cited: 58
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges
Lorenzo Guidi, Gloria Pellizzari, Paolo Tarantino, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1130-1130
Open Access | Times Cited: 39
Lorenzo Guidi, Gloria Pellizzari, Paolo Tarantino, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1130-1130
Open Access | Times Cited: 39
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?
Francesca Ruzzi, Chiara Cappello, Maria Sofia Semprini, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 11
Francesca Ruzzi, Chiara Cappello, Maria Sofia Semprini, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 11
Cholesterol metabolism in tumor microenvironment: cancer hallmarks and therapeutic opportunities
Wen G. Jiang, Weilin Jin, Aman Xu
International Journal of Biological Sciences (2024) Vol. 20, Iss. 6, pp. 2044-2071
Open Access | Times Cited: 9
Wen G. Jiang, Weilin Jin, Aman Xu
International Journal of Biological Sciences (2024) Vol. 20, Iss. 6, pp. 2044-2071
Open Access | Times Cited: 9
Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers
Yi Rao, Zachary V. Samuels, Lukas M. Carter, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 14
Open Access | Times Cited: 18
Yi Rao, Zachary V. Samuels, Lukas M. Carter, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 14
Open Access | Times Cited: 18
Rosuvastatin attenuates total-tau serum levels and increases expression of miR-124-3p in dyslipidemic Alzheimer's patients: a historic cohort study
Farnoosh Usefi, Auob Rustamzadeh, Zahra Ghobadi, et al.
Metabolic Brain Disease (2024) Vol. 39, Iss. 6, pp. 1201-1211
Closed Access | Times Cited: 4
Farnoosh Usefi, Auob Rustamzadeh, Zahra Ghobadi, et al.
Metabolic Brain Disease (2024) Vol. 39, Iss. 6, pp. 1201-1211
Closed Access | Times Cited: 4
[64Cu]Cu-NOTA-Trastuzumab and [89Zr]Zr-DFO-Trastuzumab in Xenografts with Varied HER2 Expression
Cristina Simó, Shayla Shmuel, Alex Vanover, et al.
Molecular Pharmaceutics (2024)
Closed Access | Times Cited: 4
Cristina Simó, Shayla Shmuel, Alex Vanover, et al.
Molecular Pharmaceutics (2024)
Closed Access | Times Cited: 4
Integrating molecular imaging and transcriptomic profiling in advanced HER2-positive breast cancer receiving trastuzumab emtansine (T-DM1): an analysis of the ZEPHIR clinical trial
Mattia Rediti, Danai Fimereli, Magdalena Mileva, et al.
Clinical Cancer Research (2024) Vol. 31, Iss. 1, pp. 110-121
Closed Access | Times Cited: 4
Mattia Rediti, Danai Fimereli, Magdalena Mileva, et al.
Clinical Cancer Research (2024) Vol. 31, Iss. 1, pp. 110-121
Closed Access | Times Cited: 4
Core–Shell Nanoparticles with Sequential Drug Release Depleting Cholesterol for Reverse Tumor Multidrug Resistance
Jieke Zhang, Yingying Zhou, Jialing Guo, et al.
ACS Applied Materials & Interfaces (2025)
Closed Access
Jieke Zhang, Yingying Zhou, Jialing Guo, et al.
ACS Applied Materials & Interfaces (2025)
Closed Access
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Targeting secretory autophagy in solid cancers: mechanisms, immune regulation and clinical insights
Xinyu Li, Haiying Zhao
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Xinyu Li, Haiying Zhao
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients
Lijuan He, Ben Liu, Zhuanfang Wang, et al.
Current Treatment Options in Oncology (2025)
Closed Access
Lijuan He, Ben Liu, Zhuanfang Wang, et al.
Current Treatment Options in Oncology (2025)
Closed Access
Caveolae: Metabolic Platforms at the Crossroads of Health and Disease
David Stea, Alessio D’Alessio
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 2918-2918
Open Access
David Stea, Alessio D’Alessio
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 2918-2918
Open Access
PCSK9 Promotes the Malignancy of Triple‐negative Breast Cancer Cells by Reducing Cholesterol Levels at the Plasma Membrane to Activate EGFR and HER3
Tianhong Li, Renfei Wu, Kathy Qian Luo
Advanced Science (2025)
Open Access
Tianhong Li, Renfei Wu, Kathy Qian Luo
Advanced Science (2025)
Open Access
Positron Emission Tomography and Optical Imaging to Monitor Bioorthogonal Diels–Alder Click Chemistry of Trastuzumab with a Porphyrin
Sara R.D. Gamelas, Shayla Shmuel, Cristina Simó, et al.
Bioconjugate Chemistry (2025)
Closed Access
Sara R.D. Gamelas, Shayla Shmuel, Cristina Simó, et al.
Bioconjugate Chemistry (2025)
Closed Access
Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer
Abbey Zidel, Alex Benton, Emma Brown, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Abbey Zidel, Alex Benton, Emma Brown, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Immuno-PET Detects Antibody–Drug Potency on Coadministration with Statins
Emma Brown, Shayla Shmuel, Komal Mandleywala, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 10, pp. 1638-1646
Closed Access | Times Cited: 8
Emma Brown, Shayla Shmuel, Komal Mandleywala, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 10, pp. 1638-1646
Closed Access | Times Cited: 8
Caveolin-1 knockout mitigates breast cancer metastasis to the lungs via integrin α3 dysregulation in 4T1-induced syngeneic breast cancer model
Dhirendra P. Singh, Rashmi Pathak, Naveen Chintalaramulu, et al.
Cancer Gene Therapy (2024) Vol. 31, Iss. 11, pp. 1658-1668
Open Access | Times Cited: 2
Dhirendra P. Singh, Rashmi Pathak, Naveen Chintalaramulu, et al.
Cancer Gene Therapy (2024) Vol. 31, Iss. 11, pp. 1658-1668
Open Access | Times Cited: 2
Cholesterol: the driving force behind the remodeling of tumor microenvironment in colorectal cancer
Ke Wang, Yuanyuan Zhang, Chengshuai Si, et al.
Heliyon (2024) Vol. 10, Iss. 23, pp. e39425-e39425
Open Access | Times Cited: 2
Ke Wang, Yuanyuan Zhang, Chengshuai Si, et al.
Heliyon (2024) Vol. 10, Iss. 23, pp. e39425-e39425
Open Access | Times Cited: 2
Sustained Endocytosis Inhibition via Locally‐Injected Drug‐Eluting Hydrogel Improves ADCC‐Mediated Antibody Therapy in Colorectal Cancer
Chong Wu, Xiaoting Liu, Rong Liu, et al.
Advanced Science (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 2
Chong Wu, Xiaoting Liu, Rong Liu, et al.
Advanced Science (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 2
PET and Optical Imaging of Caveolin-1 in Gastric Tumors
Sandeep Surendra Panikar, Shayla Shmuel, Jason S. Lewis, et al.
ACS Omega (2023) Vol. 8, Iss. 39, pp. 35884-35892
Open Access | Times Cited: 4
Sandeep Surendra Panikar, Shayla Shmuel, Jason S. Lewis, et al.
ACS Omega (2023) Vol. 8, Iss. 39, pp. 35884-35892
Open Access | Times Cited: 4
Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort
Arif Akyıldız, Deniz Can Güven, Hasan Çağrı Yıldırım, et al.
Medicine (2023) Vol. 102, Iss. 18, pp. e33677-e33677
Open Access | Times Cited: 3
Arif Akyıldız, Deniz Can Güven, Hasan Çağrı Yıldırım, et al.
Medicine (2023) Vol. 102, Iss. 18, pp. e33677-e33677
Open Access | Times Cited: 3
Metformin-Induced Receptor Turnover Alters Antibody Accumulation in HER-Expressing Tumors
Sandeep Surendra Panikar, Nai Keltee, Na-Keysha Berry, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 8, pp. 1195-1202
Open Access | Times Cited: 2
Sandeep Surendra Panikar, Nai Keltee, Na-Keysha Berry, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 8, pp. 1195-1202
Open Access | Times Cited: 2
A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells
Alain Aguilar‐Valdés, Francisco González‐Vela, Hilda Sánchez‐Vidal, et al.
PROTEOMICS (2023) Vol. 23, Iss. 16
Closed Access | Times Cited: 1
Alain Aguilar‐Valdés, Francisco González‐Vela, Hilda Sánchez‐Vidal, et al.
PROTEOMICS (2023) Vol. 23, Iss. 16
Closed Access | Times Cited: 1
